Aaron Wealth Advisors LLC lessened its holdings in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 3.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 65,685 shares of the company’s stock after selling 2,306 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Kura Oncology were worth $572,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Hsbc Holdings PLC raised its holdings in shares of Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after buying an additional 2,167 shares in the last quarter. HighVista Strategies LLC bought a new position in shares of Kura Oncology during the second quarter valued at $345,000. Integral Health Asset Management LLC bought a new position in shares of Kura Oncology during the second quarter valued at $2,059,000. Marshall Wace LLP acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at $541,000. Finally, Armistice Capital LLC grew its holdings in shares of Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares during the last quarter.
Kura Oncology Price Performance
Shares of KURA stock opened at $7.26 on Monday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $6.98 and a 12 month high of $24.17. The firm has a market cap of $564.54 million, a price-to-earnings ratio of -3.08 and a beta of 0.81. The stock has a 50-day moving average price of $10.51 and a 200 day moving average price of $16.33.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Kura Oncology
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Read More
- Five stocks we like better than Kura Oncology
- The Most Important Warren Buffett Stock for Investors: His Own
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- How to trade using analyst ratings
- Oilfield Leader SLB: An AI Name You Need to Know
- Are Penny Stocks a Good Fit for Your Portfolio?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA – Free Report).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.